Tag: solid tumors

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

Crescent Biopharma to Present at June Investor Conferences

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions

Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics...

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published...

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc completes pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsSolid tumors

Winners of the 2026 Excellence in Retailing Awards Announced

Xinhua Silk Road: Chinese tire manufacturer Sailun Group showcases green innovation at WBCSD annual meeting

Xinhua Silk Road: Chinese tire manufacturer Sailun Group showcases green innovation at WBCSD annual meeting

Tag: solid tumors

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

Crescent Biopharma to Present at June Investor Conferences

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

/C O R R E C T I O N — Ranok Therapeutics/

Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us